D-dimer can predict survival in patients with chronic atrial fibrillation

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 5, 2004, Pages 413-417

  Mahé, Isabelle ^a   Drouet, Ludovic ^a   Simoneau, Guy ^a   Minh Muzeaux, Sophie ^a   Caulin, Charles ^a   Bergmann, Jean François ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Atrial fibrillation; D dimer; Death; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; D DIMER;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SURVIVAL;

EID: 3142621135     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000114440.81125.bd     Document Type: Article

References (12)

1. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE/. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119:194S-206S.
2. Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis. Clin Sci 1995; 89:205-214.
3. Lip GYH, Lip PL, Zarifis J, Watson RD, Baregord D, Lowe G, Beevers DG. Fibrin D-dimers and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation 1996; 94: 425-431.
4. Roldan V, Marin F, Blann A, Garcia A, MarcoP, Sogorb F, Lip GYH. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24:1373-1380.
5. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90:1163-1172.
6. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31:828-833.
7. Mané I, Drouet L, Chassany O, et al. D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation. Thromb Res 2002; 107:1-6.
8. Deguchi K, Deguchi A, Wada H, Murashima S. Study of cardiovascular risk factors and hemostatic molecular markers in elderly persons. Semin Thromb Haemost 2000; 26:23-27.
9. MacCallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Haemostatic and lipids determinants of prothrombin fragment F1,2 and D-dimer in plasma. Thromb Haemost 2000; 83:421-426.
10. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-952.
11. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89:601-609.
12. Yamaguchi T, for the Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. A prospective randomised trial. Stroke 2000; 31:817-822.